Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Total Debt: 2012-2025

Historic Total Debt for Adma Biologics (ADMA) over the last 9 years, with Sep 2025 value amounting to $72.4 million.

  • Adma Biologics' Total Debt fell 28.52% to $72.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.4 million, marking a year-over-year decrease of 28.52%. This contributed to the annual value of $72.3 million for FY2024, which is 44.61% down from last year.
  • Latest data reveals that Adma Biologics reported Total Debt of $72.4 million as of Q3 2025, which was down 1.32% from $73.4 million recorded in Q2 2025.
  • Adma Biologics' 5-year Total Debt high stood at $144.3 million for Q1 2023, and its period low was $72.3 million during Q4 2024.
  • Its 3-year average for Total Debt is $110.1 million, with a median of $130.6 million in 2023.
  • As far as peak fluctuations go, Adma Biologics' Total Debt skyrocketed by 50.56% in 2022, and later crashed by 44.61% in 2024.
  • Adma Biologics' Total Debt (Quarterly) stood at $94.9 million in 2021, then surged by 50.56% to $142.8 million in 2022, then declined by 8.57% to $130.6 million in 2023, then plummeted by 44.61% to $72.3 million in 2024, then decreased by 28.52% to $72.4 million in 2025.
  • Its last three reported values are $72.4 million in Q3 2025, $73.4 million for Q2 2025, and $72.5 million during Q1 2025.